Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Open AccessResearch

Cost-effectiveness of anti-retroviral therapy at a district hospital in southern Ethiopia

Asfaw Demissie Bikilla1,2 email, Degu Jerene3 email, Bjarne Robberstad1,4 email and Bernt Lindtjørn1 email

Center for International Health, University of Bergen, Post box 7804, 5020 Bergen, Norway

Faculty of Business and Economics, Hawassa University, PO Box 278, Hawassa, Ethiopia

Arba Minch Hospital, Arba Minch, Ethiopia

Department of Public Health and Primary Health Care, University of Bergen, Bergen, Norway

author email corresponding author email

Cost Effectiveness and Resource Allocation 2009, 7:13doi:10.1186/1478-7547-7-13

Published: 17 July 2009

Abstract

Background

As the resource implications of expanding anti-retroviral therapy (ART) are likely to be large, there is a need to explore its cost-effectiveness. So far, there is no such information available from Ethiopia.

Objective

To assess the cost-effectiveness of ART for routine clinical practice in a district hospital setting in Ethiopia.

Methods

We estimated the unit cost of HIV-related care from the 2004/5 fiscal year expenditure of Arba Minch Hospital in southern Ethiopia. We estimated outpatient and inpatient service use from HIV-infected patients who received care and treatment at the hospital between January 2003 and March 2006. We measured the health effect as life years gained (LYG) for patients receiving ART compared with those not receiving such treatment. The study adopted a health care provider perspective and included both direct and overhead costs. We used Markov model to estimate the lifetime costs, health benefits and cost-effectiveness of ART.

Findings

ART yielded an undiscounted 9.4 years expected survival, and resulted in 7.1 extra LYG compared to patients not receiving ART. The lifetime incremental cost is US$2,215 and the undiscounted incremental cost per LYG is US$314. When discounted at 3%, the additional LYG decreases to 5.5 years and the incremental cost per LYG increases to US$325.

Conclusion

The undiscounted and discounted incremental costs per LYG from introducing ART were less than the per capita GDP threshold at the base year. Thus, ART could be regarded as cost-effective in a district hospital setting in Ethiopia.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.